{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:19:05Z","timestamp":1790893145884,"version":"4.1.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T00:00:00Z","timestamp":1647302400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jaadinternational.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD International"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.jdin.2022.03.007","type":"journal-article","created":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T20:35:42Z","timestamp":1650486942000},"page":"156-163","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Modulation of the kappa and mu opioid axis for the treatment of chronic pruritus: A review of basic science and clinical implications"],"prefix":"10.1016","volume":"7","author":[{"given":"Sarina","family":"Elmariah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Chisolm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Sciascia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn G.","family":"Kwatra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdin.2022.03.007_bib1","first-page":"1","article-title":"Clinical characteristics and outcomes of end-stage renal disease patients with self-reported pruritus symptoms","volume":"7","author":"Ramakrishnan","year":"2013","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"10.1016\/j.jdin.2022.03.007_bib2","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3347","article-title":"A new generation of treatments for itch","volume":"100","author":"Fowler","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jdin.2022.03.007_bib3","doi-asserted-by":"crossref","first-page":"699","DOI":"10.3390\/medicina55100699","article-title":"Impact of pruritus on sleep quality of hemodialysis patients: a systematic review and meta-analysis","volume":"55","author":"Rehman","year":"2019","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.jdin.2022.03.007_bib4","first-page":"e5178","article-title":"Uremic pruritus: prevalence and impact on quality of life and depressive symptoms in hemodialysis patients","volume":"11","author":"Satti","year":"2019","journal-title":"Cureus"},{"key":"10.1016\/j.jdin.2022.03.007_bib5","article-title":"Treatment and burden of disease in a cohort of patients with prurigo nodularis: a survey-based study","volume":"100","author":"Todberg","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jdin.2022.03.007_bib6","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.jid.2019.07.697","article-title":"Real-world prevalence of prurigo nodularis and burden of associated diseases","volume":"140","author":"Huang","year":"2020","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jdin.2022.03.007_bib7","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.jid.2020.08.020","article-title":"Health-related QOL and economic burden of chronic pruritus","volume":"141","author":"Whang","year":"2021","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jdin.2022.03.007_bib8","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.neuron.2014.02.046","article-title":"Dynorphin acts as a neuromodulator to inhibit itch in the dorsal horn of the spinal cord","volume":"82","author":"Kardon","year":"2014","journal-title":"Neuron"},{"key":"10.1016\/j.jdin.2022.03.007_bib9","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.neuron.2018.08.044","article-title":"Kappa opioid receptor distribution and function in primary afferents","volume":"99","author":"Snyder","year":"2018","journal-title":"Neuron"},{"key":"10.1016\/j.jdin.2022.03.007_bib10","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1038\/s41386-018-0225-3","article-title":"Untangling the complexity of opioid receptor function","volume":"43","author":"Valentino","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jdin.2022.03.007_bib11","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jopan.2018.06.098","article-title":"Prophylactic nalbuphine to prevent neuraxial opioid-induced pruritus: a systematic review and meta-analysis of randomized controlled trials","volume":"34","author":"Tubog","year":"2019","journal-title":"J Perianesth Nurs"},{"key":"10.1016\/j.jdin.2022.03.007_bib12","doi-asserted-by":"crossref","first-page":"249","DOI":"10.36076\/ppj.2011\/14\/249","article-title":"Peripherally acting opioids and clinical implications for pain control","volume":"14","author":"Sehgal","year":"2011","journal-title":"Pain Phys"},{"key":"10.1016\/j.jdin.2022.03.007_bib13","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1177\/2049463720911986","article-title":"Basic opioid pharmacology---an update","volume":"14","author":"James","year":"2020","journal-title":"Br J Pain"},{"key":"10.1016\/j.jdin.2022.03.007_bib14","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1159\/000082563","article-title":"Changes of epidermal mu-opiate receptor expression and nerve endings in chronic atopic dermatitis","volume":"210","author":"Bigliardi-Qi","year":"2005","journal-title":"Dermatology"},{"key":"10.1016\/j.jdin.2022.03.007_bib15","doi-asserted-by":"crossref","first-page":"555","DOI":"10.2340\/00015555-1353","article-title":"Systemic kappa opioid receptor agonists in the treatment of chronic pruritus: a literature review","volume":"92","author":"Phan","year":"2012","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jdin.2022.03.007_bib16","doi-asserted-by":"crossref","first-page":"564","DOI":"10.2340\/00015555-2595","article-title":"Opioid receptors in psoriatic skin: relationship with itch","volume":"97","author":"Kupczyk","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jdin.2022.03.007_bib17","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.jaci.2018.09.005","article-title":"Itch: from mechanism to (novel) therapeutic approaches","volume":"142","author":"Yosipovitch","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jdin.2022.03.007_bib18","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1111\/jdv.16360","article-title":"Opioid receptors expression in the skin of haemodialysis patients suffering from uraemic pruritus","volume":"34","author":"Wieczorek","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jdin.2022.03.007_bib19","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/978-3-662-44605-8_11","article-title":"Itch and its inhibition by counter stimuli","volume":"226","author":"Snyder","year":"2015","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.jdin.2022.03.007_bib20","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.anai.2019.01.016","article-title":"Chronic itch management: therapies beyond those targeting the immune system","volume":"123","author":"Fowler","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jdin.2022.03.007_bib21","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/BF03020728","article-title":"Epidural naloxone reduces pruritus and nausea without affecting analgesia by epidural morphine in bupivacaine","volume":"47","author":"Choi","year":"2000","journal-title":"Can J Anaesth"},{"key":"10.1016\/j.jdin.2022.03.007_bib22","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s12630-015-0380-5","article-title":"A naloxone admixture to prevent opioid-induced pruritus in children: a randomized controlled trial","volume":"62","author":"West","year":"2015","journal-title":"Can J Anaesth"},{"key":"10.1016\/j.jdin.2022.03.007_bib23","doi-asserted-by":"crossref","first-page":"e4729","DOI":"10.1097\/MD.0000000000004729","article-title":"The effect of naloxone treatment on opioid-induced side effects: a meta-analysis of randomized and controlled trails","volume":"95","author":"He","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jdin.2022.03.007_bib24","series-title":"Naloxone hydrochloride. Package insert","year":"2019"},{"key":"10.1016\/j.jdin.2022.03.007_bib25","series-title":"Revia. Package insert","year":"2013"},{"key":"10.1016\/j.jdin.2022.03.007_bib26","doi-asserted-by":"crossref","first-page":"159","DOI":"10.5021\/ad.2016.28.2.159","article-title":"Clinical efficacy and safety of naltrexone combination therapy in older patients with severe pruritus","volume":"28","author":"Lee","year":"2016","journal-title":"Ann Dermatol"},{"key":"10.1016\/j.jdin.2022.03.007_bib27","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1093\/ndt\/gfp588","article-title":"Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a phase III, randomized, double-blind, placebo-controlled study","volume":"25","author":"Kumagai","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jdin.2022.03.007_bib28","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.1681\/ASN.2005020152","article-title":"Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies","volume":"16","author":"Wikstr\u00f6m","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jdin.2022.03.007_bib29","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.ekir.2020.01.006","article-title":"Randomized controlled trial of difelikefalin for chronic pruritus in hemodialysis patients","volume":"5","author":"Fishbane","year":"2020","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.jdin.2022.03.007_bib30","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1912770","article-title":"KALM-1 Trial Investigators. A phase 3 trial of difelikefalin in hemodialysis patients with pruritus","volume":"382","author":"Fishbane","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdin.2022.03.007_bib31","series-title":"Korsuva (difelikefalin). Package insert","year":"2021"},{"key":"10.1016\/j.jdin.2022.03.007_bib32","unstructured":"Cara therapeutics announces topline results from KARE phase 2 dose-ranging trial of oral KORSUVA\u2122 in atopic dermatitis patients with moderate-to-severe pruritus. Press release. Cara Therapeutics. April 29, 2021. Accessed April 4, 2022. https:\/\/www.biospace.com\/article\/releases\/cara-therapeutics-announces-topline-results-from-kare-phase-2-dose-ranging-trial-of-oral-korsuva-in-atopic-dermatitis-patients-with-moderate-to-severe-pruritus"},{"key":"10.1016\/j.jdin.2022.03.007_bib33","series-title":"Butorphanol tartrate. Package insert","year":"2015"},{"key":"10.1016\/j.jdin.2022.03.007_bib34","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0885-3924(96)00154-6","article-title":"Transnasal butorphanol for the treatment of opioid-induced pruritus unresponsive to antihistamines","volume":"12","author":"Dunteman","year":"1996","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.jdin.2022.03.007_bib35","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1046\/j.1460-9592.2000.00447.x","article-title":"Continuous epidural butorphanol relieves pruritus associated with epidural morphine infusions in children","volume":"10","author":"Gunter","year":"2000","journal-title":"Paediatr Anaesth"},{"key":"10.1016\/j.jdin.2022.03.007_bib36","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s12630-013-9989-4","article-title":"Butorphanol prevents morphine-induced pruritus without increasing pain and other side effects: a systematic review of randomized controlled trials","volume":"60","author":"Du","year":"2013","journal-title":"Can J Anaesth"},{"key":"10.1016\/j.jdin.2022.03.007_bib37","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.jaad.2020.07.017","article-title":"Intranasal butorphanol rescue therapy for the treatment of intractable pruritus: a case series from the Johns Hopkins Itch Clinic","volume":"83","author":"Khanna","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jdin.2022.03.007_bib38","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jaad.2005.12.010","article-title":"Butorphanol for treatment of intractable pruritus","volume":"54","author":"Dawn","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jdin.2022.03.007_bib39","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/0376-8716(85)90066-3","article-title":"Nalbuphine","volume":"14","author":"Schmidt","year":"1985","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.jdin.2022.03.007_bib40","series-title":"Nalbuphine hydrochloride. Package insert","year":"2020"},{"key":"10.1016\/j.jdin.2022.03.007_bib41","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1159\/000484573","article-title":"TR02 Study Investigators. A multicenter, randomized, double-blind, placebo-controlled trial of nalbuphine ER tablets for uremic pruritus","volume":"46","author":"Mathur","year":"2017","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.jdin.2022.03.007_bib42","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/jdv.17816","article-title":"Efficacy and safety of oral nalbuphine extended release in prurigo nodularis: results of a phase 2 randomized controlled trial with an open-label extension phase","volume":"36","author":"Weisshaar","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jdin.2022.03.007_bib43","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2340\/00015555-3164","article-title":"European S2k guideline on chronic pruritus","volume":"99","author":"Weisshaar","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jdin.2022.03.007_bib44","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jpainsymman.2019.10.003","article-title":"Development and validation of a uremic pruritus treatment algorithm and patient information toolkit in patients with chronic kidney disease and end stage kidney disease","volume":"59","author":"Ragazzo","year":"2020","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.jdin.2022.03.007_bib45","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.jaad.2020.07.025","article-title":"Practical approaches for diagnosis and management of prurigo nodularis: United States expert panel consensus","volume":"84","author":"Elmariah","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jdin.2022.03.007_bib46","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/cpt197213178","article-title":"Evaluation of nalbuphine for abuse potential","volume":"13","author":"Jasinski","year":"1972","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jdin.2022.03.007_bib47","doi-asserted-by":"crossref","first-page":"823","DOI":"10.5414\/CP201852","article-title":"One year long-term study on abuse liability of nalfurafine in hemodialysis patients","volume":"51","author":"Ueno","year":"2013","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.jdin.2022.03.007_bib48","unstructured":"Lists of: scheduling actions controlled substances regulated chemicals. Drug Enforcement Administration. November 2021. Accessed April 4, 2022. https:\/\/www.deadiversion.usdoj.gov\/schedules\/orangebook\/orangebook.pdf"},{"key":"10.1016\/j.jdin.2022.03.007_bib49","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/978-3-662-44605-8_16","article-title":"Targeting itch with ligands selective for \u03ba opioid receptors","volume":"226","author":"Cowan","year":"2015","journal-title":"Handb Exp Pharmacol"}],"container-title":["JAAD International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666328722000360?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666328722000360?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T21:00:29Z","timestamp":1762981229000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666328722000360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":49,"alternative-id":["S2666328722000360"],"URL":"https:\/\/doi.org\/10.1016\/j.jdin.2022.03.007","relation":{},"ISSN":["2666-3287"],"issn-type":[{"value":"2666-3287","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modulation of the kappa and mu opioid axis for the treatment of chronic pruritus: A review of basic science and clinical implications","name":"articletitle","label":"Article Title"},{"value":"JAAD International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdin.2022.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}